statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	280
DE - Germania	179
SG - Singapore	104
CN - Cina	85
IT - Italia	61
BD - Bangladesh	53
HK - Hong Kong	41
VN - Vietnam	25
BR - Brasile	24
RU - Federazione Russa	18
FR - Francia	17
NL - Olanda	17
IN - India	13
GB - Regno Unito	11
FI - Finlandia	9
SE - Svezia	9
ID - Indonesia	7
CA - Canada	6
ZA - Sudafrica	6
CI - Costa d'Avorio	5
KR - Corea	4
PL - Polonia	4
CZ - Repubblica Ceca	3
IE - Irlanda	3
JP - Giappone	3
AU - Australia	2
CL - Cile	2
CO - Colombia	2
DK - Danimarca	2
ES - Italia	2
GT - Guatemala	2
NP - Nepal	2
TN - Tunisia	2
TR - Turchia	2
AM - Armenia	1
AR - Argentina	1
BA - Bosnia-Erzegovina	1
BB - Barbados	1
BH - Bahrain	1
CR - Costa Rica	1
ET - Etiopia	1
GE - Georgia	1
GR - Grecia	1
HN - Honduras	1
IL - Israele	1
IR - Iran	1
JO - Giordania	1
KE - Kenya	1
LA - Repubblica Popolare Democratica del Laos	1
NI - Nicaragua	1
NO - Norvegia	1
NZ - Nuova Zelanda	1
PK - Pakistan	1
PR - Porto Rico	1
PY - Paraguay	1
SA - Arabia Saudita	1
TM - Turkmenistan	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	1.032

Nome	#
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients	222
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab	192
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy	170
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis	119
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications	105
Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review	95
Denosumab versus zoledronic acid: analgesic and survival impact of an extended treatment regimen beyond 2 years in breast cancer	78
Denosumab versus zoledronic acid in metastatic breast cancer: A retrospective observational analysis of 24-dose regimens on analgesia and skeletal-related event prevention	78
Totale	1.059

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	4	0	0	0	0	0	0	0	2	0	0	0	2
2022/2023	57	5	7	4	2	8	10	3	6	6	0	6	0
2023/2024	137	0	4	1	2	11	6	22	19	9	18	24	21
2024/2025	241	18	18	19	25	13	5	8	17	13	29	18	58
2025/2026	620	54	47	52	31	32	22	79	27	79	54	100	43
Totale													1.059

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca